{'fraction_non_alphanumeric': 0.023880597014925373, 'fraction_numerical': 0.005970149253731343, 'mean_word_length': 5.578431372549019, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Screening blood: public health and medical uncertainty.


 In March 1985, the Food and Drug Administration approved the first of five applications from drug companies to market a blood test kit to detect antibodies to HTLV-III, a virus linked with acquired immunodeficiency syndrome (AIDS). The authors discuss the reliability of the antibody test, the immediate problems it raises concerning notification and confidentiality, and the long-term questions that AIDS-antibody testing poses about mass screening, mandatory reporting of positive results to public health officials, behavioral change, and public health interventions under conditions of medical uncertainty.
